NOVO — Januar 2026
-
-
SEATTLE, January 09, 2026--(BUSINESS WIRE)--Amazon Pharmacy (NASDAQ: AMZN), a full-service digital pharmacy that delivers medications directly to customers' homes, now offers Novo Nordisk’s Wegovy
pill, the first and only FDA-approved oral GLP-1 for weight management, through many insurance plans as well as a transparent cash-pay option.Amazon Pharmacy Expands Access to New Wegovy® Pill with Insurance and Cash-Pay Options
SEATTLE, January 09, 2026--Amazon Pharmacy now offers Novo Nordisk’s newly FDA-approved oral GLP-1 with transparent pricing and fast, free home delivery
Yahoo Finance (finance.yahoo.com)
-
Amazon vil fremover sælge Novo Nordisk Wegovy-pille https://proinvestor.com/investornyt/1401479/amazon-vil-fremover-saelge-novo-nordisk-wegovy-pille
-
Ny bragende succes på vej til Novo Nordisk? Rammer topchef Mike Doustdar bolden rigtigt denne gang? https://www.linkedin.com/posts/olehall_ny-bragende-succes-på-vej-til-novo-nordisk-activity-7415348622005088257-aosR/?originalSubdomain=dk
-
CICC initiates coverage on Novo Nordisk $NVO with a buy rating and a $73.5 price target
-
Novo-investorerne har tjent trecifret milliardbeløb i optursuge https://proinvestor.com/investornyt/1401536/novo-investorerne-har-tjent-trecifret-milliardbelob-i-optursuge
-
Solgte Novo Nordisk (NOVO-B) omkring 386 DKK. To hovedrisici: Teknologisk prispres
AI, automation og robotteknologi reducerer produktionsomkostninger på insulin og GLP-1-produkter. Wegovy-pillen (oral) lanceret januar 2026 til $149/måned (starterdosis 1.5 mg cash-pay; højere doser $199–299). Konkurrence fra Lillys orforglipron (forventet FDA-godkendelse primo 2026) accelererer commoditization. På sigt nærmer medicinpriser sig marginalomkostninger nær nul.
Geopolitisk risiko: -
Eskalerende spændinger DK/Grønland-USA. Trump gentog 9. januar 2026 trusler om overtagelse "whether they like it or not" (med reference til national security og risiko for russisk/kinesisk indflydelse). Potentielle NATO-implikationer og handelsusikkerhed. Novo har høj US-eksponering.
-
Godmorgen
-
@stockbull5:10: Tak for at dele dine overvejelser ang. for at sælge NOVO - og andre aktier: Jeg har forståelsen, at det er en strategisk overvejelse? - To spørgsmål: Er du ude af danske aktier udelukkende pgr af geopolitisk usikkerhed? Eller var der andre overvejelser også? - Du skriver 2 hovedrisici? Og derefter, at du ser reducerede produktionsomkostninger? Det står vel i modsætning til hinanden og til, at du ser, at forskellen mellem medicinpriser og marginalomkostninger nærmer sig nul?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind